DMAC Stock Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
DiaMedica Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.21|
|52 Week High||US$4.80|
|52 Week Low||US$1.15|
|1 Month Change||-31.25%|
|3 Month Change||-40.10%|
|1 Year Change||-69.29%|
|3 Year Change||-36.65%|
|5 Year Change||-81.33%|
|Change since IPO||-96.38%|
Recent News & Updates
FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|DMAC||US Biotechs||US Market|
Return vs Industry: DMAC underperformed the US Biotechs industry which returned -22.7% over the past year.
Return vs Market: DMAC underperformed the US Market which returned -20% over the past year.
|DMAC Average Weekly Movement||16.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: DMAC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: DMAC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company’s lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.
DiaMedica Therapeutics Fundamentals Summary
|DMAC fundamental statistics|
Is DMAC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DMAC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||0.00%|
How did DMAC perform over the long term?See historical performance and comparison
Is DMAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DMAC?
Other financial metrics that can be useful for relative valuation.
|What is DMAC's n/a Ratio?|
Price to Book Ratio vs Peers
How does DMAC's PB Ratio compare to its peers?
|DMAC PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CYCC Cyclacel Pharmaceuticals
ASLN ASLAN Pharmaceuticals
AIKI AIkido Pharma
IDRA Idera Pharmaceuticals
DMAC DiaMedica Therapeutics
Price-To-Book vs Peers: DMAC is expensive based on its Price-To-Book Ratio (0.8x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does DMAC's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: DMAC is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is DMAC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate DMAC's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of DMAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DMAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DMAC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is DiaMedica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMAC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DMAC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DMAC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DMAC is forecast to have no revenue next year.
High Growth Revenue: DMAC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DMAC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has DiaMedica Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DMAC is currently unprofitable.
Growing Profit Margin: DMAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DMAC is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare DMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: DMAC has a negative Return on Equity (-35.96%), as it is currently unprofitable.
Discover strong past performing companies
How is DiaMedica Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DMAC's short term assets ($39.2M) exceed its short term liabilities ($1.5M).
Long Term Liabilities: DMAC's short term assets ($39.2M) exceed its long term liabilities ($7.0K).
Debt to Equity History and Analysis
Debt Level: DMAC is debt free.
Reducing Debt: DMAC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DMAC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DMAC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.2% each year
Discover healthy companies
What is DiaMedica Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|DiaMedica Therapeutics Dividend Yield vs Market|
|Company (DiaMedica Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (DiaMedica Therapeutics)||n/a|
Notable Dividend: Unable to evaluate DMAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DMAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DMAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DMAC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DMAC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Pauls (51 yo)
Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...
CEO Compensation Analysis
|Rick Pauls's Compensation vs DiaMedica Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$1m||US$477k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$878k||US$455k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$420k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$734k||US$315k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$502k||US$280k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$388k||US$276k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$289k||US$180k|
Compensation vs Market: Rick's total compensation ($USD1.14M) is above average for companies of similar size in the US market ($USD772.75K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
Experienced Management: DMAC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: DMAC's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DMAC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|08 Jul 22||BuyUS$275,898||Thomas von Koch||Individual||207,974||US$1.33|
|08 Jul 22||BuyUS$400,197||Thomas von Koch||Individual||304,827||US$1.36|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
DiaMedica Therapeutics Inc.'s employee growth, exchange listings and data sources
- Name: DiaMedica Therapeutics Inc.
- Ticker: DMAC
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$32.789m
- Shares outstanding: 26.44m
- Website: https://www.diamedica.com
Number of Employees
- DiaMedica Therapeutics Inc.
- Two Carlson Parkway
- Suite 260
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DMAC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Mar 2007|
|F2KA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.